ClinicalTrials.gg
CompletedNCT01854775Updated Jan 9, 2026Results posted

Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children

A Phase 2/3 interventional study of E/C/F/TAF and E/C/F/TAF (Low Dose) in Acquired Immune Deficiency Syndrome (AIDS) and HIV Infections, sponsored by Gilead Sciences. Completed at 16 sites in 5 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-01-09.

Sponsored by Gilead Sciences · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
129
Allocation
Non-randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing cobicistat in Acquired Immunodeficiency Syndrome — none open to participants now, 1 under way, 1 of them phase 3. Cobicistat · Acquired Immunodeficiency Syndrome.

Enrollment
7th of 16
129 · median 116
Started
2013
with 3 others
Phase 2/3
2 of 16
none open now
Registered
6th of 16
by date
Lead sponsor
7 of 16
Gilead Sciences

Among the 16 studies testing cobicistat in Acquired Immunodeficiency Syndrome, this one is the 7th largest by enrollment, is one of 4 that started in 2013, is one of 2 in phase 2/3, and was the 6th registered.

Acquired Immunodeficiency Syndrome

3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

Browse Acquired Immunodeficiency Syndrome studies →

Open to participants now

None of the 16 studies testing cobicistat in Acquired Immunodeficiency Syndrome is open now. The open studies under Acquired Immunodeficiency Syndrome, anywhere →

About cobicistat

Cobicistat: first FDA approval 2012 (STRIBILD), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 198 Acquired Immunodeficiency Syndrome studies recruiting now, 118 (60%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing cobicistat in Acquired Immunodeficiency Syndrome as a file.
02

Study summary

The primary objectives of Cohort 1 are to evaluate the steady state pharmacokinetics (PK) for elvitegravir (EVG) and tenofovir alafenamide (TAF) and confirm the dose of the elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) STR (Part A) and to evaluate the safety and tolerability of E/C/F/TAF STR through Week 24 (Part B) in human immunodeficiency virus - 1 (HIV-1) infected, antiretroviral (ARV) treatment-naive adolescents.

The primary objectives of Cohort 2 are to evaluate the PK of EVG and TAF (Part A), and to evaluate the safety and tolerability of E/C/F/TAF through Week 24 (Part B) in virologically suppressed HIV-1 infection children 6 to \< 12 years weighing >= 25 kg.

The primary objectives of Cohort 3 are to evaluate the PK of EVG and TAF and confirm the dose of the STR, and to evaluate the safety and tolerability of E/C/F/TAF low dose (LD) STR in virologically suppressed HIV-1 infected children ≥ 2 years of age and weighing ≥ 14 to \< 25 kg.

03

Conditions studied

  • Acquired Immune Deficiency Syndrome (AIDS)
  • HIV Infections

Keywords

  • Adolescents
  • HIV-1
  • HIV
  • Treatment-naive
  • Virologically suppressed
  • Children
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Cohort 1

    • Age at baseline: 12 years to \< 18 years old
    • Weight at screening: ≥ 35 kg (77 lbs)
    • Plasma -1 ribonucleic acid (RNA) levels of ≥ 1,000 copies/mL at screening (Roche COBAS TaqMan v2.0)
    • Screening genotype report shows sensitivity to EVG, emtricitabine (FTC) and tenofovir (TFV)
    • No prior use of any approved or experimental anti-HIV-1 drug for any length of time
  • Cohort 2

    • Age at baseline: 6 years to \< 12 years old
    • Weight at screening: ≥ 25 kg (55 lbs)
    • Plasma HIV-1 RNA of \< 50 copies/mL (or undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is > 50 copies/mL) for ≥ 180 consecutive days (6 months) prior to screening on a stable antiretroviral regimen, without documented history of resistance to any component of E/C/F/TAF STR.
  • Cohort 3

    • Age at baseline: ≥ 2 years old
    • Weight at screening: ≥ 14 kg (31 lbs) to \< 25 kg (55 lbs)
    • Plasma HIV-1 RNA: \< 50 copies/mL (or undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is > 50 copies/mL) for ≥ 180 consecutive days (6 months) prior to screening on a stable antiretroviral regimen, without prior history of resistance to any component of E/C/F/TAF STR

Key Exclusion Criteria:

  • or virus infection
  • Evidence of active pulmonary or extra-pulmonary tuberculosis disease within 3 months of the screening visit.
  • Individuals experiencing decompensated cirrhosis
  • Pregnant or lactating females

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
129 participants (actual)

Study arms

  • Experimental
    Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg

    Treatment naive adolescents (12 to \< 18 years of age) living with human immunodeficiency virus (HIV) will receive E/C/F/TAF (150/150/200/10 mg) fixed-dose combination (FDC) once daily for 48 weeks. Participants who complete 48 weeks of study treatment will have the option to receive E/C/F/TAF in an extension phase of the study until: a) the participant turns 18 years old and E/C/F/TAF is commercially available for adults in the country in which the participant is enrolled; b) age-appropriate E/C/F/TAF become commercially available in the country in which the participant is enrolled; or c) Gilead elects to terminate development of E/C/F/TAF in that country.

    Drug: E/C/F/TAF

  • Experimental
    Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg

    Children (6 to \< 12 years of age weighing ≥ 25 kg) with HIV who were virologically suppressed will receive E/C/F/TAF (150/150/200/10 mg) FDC once daily for 48 weeks. Participants who complete 48 weeks of study treatment will have the option to receive E/C/F/TAF in an extension phase of the study until: a) the participant turns 18 years old and E/C/F/TAF is commercially available for adults in the country in which the participant is enrolled; b) age-appropriate E/C/F/TAF become commercially available in the country in which the participant is enrolled; or c) Gilead elects to terminate development of E/C/F/TAF in that country.

    Drug: E/C/F/TAF

  • Experimental
    Cohort 3: Age ≥2 Years and Weight ≥ 14 to <25 kg

    Children (≥ 2 years of age weighing ≥ 14 to \< 25 kg) with HIV who were virologically suppressed will receive E/C/F/TAF (90/90/120/6 mg) FDC once daily for 48 weeks. Participants who attain a weight of ≥ 25 kg during the course of the study will switch to adult E/C/F/TAF (150/150/200/10 mg) tablets administered orally, once daily with food. Participants who complete 48 weeks of study treatment will have the option to receive E/C/F/TAF in an extension phase of the study until: a) the participant turns 18 years old and E/C/F/TAF is commercially available for adults in the country in which the participant is enrolled; b) age-appropriate E/C/F/TAF became commercially available in the country in which the participant is enrolled; or c) Gilead elects to terminate development of E/C/F/TAF in that country.

    Drug: E/C/F/TAF · Drug: E/C/F/TAF (Low Dose)

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic (PK) Parameter: AUCtau of Elvitegravir (EVG) (Cohort 1)

    AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval).

    Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 5 minutes, 0.25, 0.5, 1, 1.5, 2, 4, 5, 8 and 24 hours post-dose at Week 4

  2. PK Parameter: AUCtau of EVG (Cohort 2)

    AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval).

    Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose at Week 4

  3. PK Parameter: AUCtau of EVG (Cohort 3)

    AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval).

    Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 8 hours post-dose at Week 2

  4. PK Parameter: AUClast of Tenofovir Alafenamide (TAF) (Cohort 1)

    AUClast is defined as the concentration of drug from time zero to the last observable concentration, area under the concentration time curve to last observation (AUClast).

    Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 5 minutes, 0.25, 0.5, 1, 1.5, 2, 4, 5, 8 and 24 hours post-dose at Week 4

  5. PK Parameter: AUClast of TAF (Cohort 2)

    AUClast is defined as the concentration of drug from time zero to the last observable concentration.

    Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose at Week 4

  6. PK Parameter: AUCtau of TAF (Cohort 3)

    AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval).

    Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 8 hours post-dose at Week 2

  7. Cohort 1: Percentage of Participants With All Treatment-Emergent Adverse Events (AEs) and Treatment-Emergent Serious Adverse Events (SAEs)

    Treatment-emergent adverse events (TEAEs) were defined as any AEs that begin or worsen on or after the start of study drug through 30 days after the last dose of study drug. The severity was graded based on the Gilead Sciences Grading Scale for Severity of Adverse Events. An AE that met one or more of the following outcomes was classified as serious: * Fatal * Life-threatening * Disabling/incapacitating * Results in hospitalization or prolongs a hospital stay * A congenital abnormality * Other important medical events may also be considered serious AEs if they may require medical or surgical intervention to prevent one of the outcomes listed above.

    Time frame: From first dose date up to Week 24

  8. Cohort 2: Percentage of Participants With All Treatment-Emergent AEs and Treatment-Emergent SAEs

    TEAEs were defined as any AEs that begin or worsen on or after the start of study drug through 30 days after the last dose of study drug. The severity was graded based on the Gilead Sciences Grading Scale for Severity of Adverse Events. An AE that met one or more of the following outcomes was classified as serious: * Fatal * Life-threatening * Disabling/incapacitating * Results in hospitalization or prolongs a hospital stay * A congenital abnormality * Other important medical events may also be considered serious AEs if they may require medical or surgical intervention to prevent one of the outcomes listed above.

    Time frame: From first dose date up to Week 24

  9. Cohort 3: Percentage of Participants With All Treatment-Emergent AEs and Treatment-Emergent SAEs

    TEAEs were defined as any AEs that begin or worsen on or after the start of study drug through 30 days after the last dose of study drug. The severity was graded based on the Gilead Sciences Grading Scale for Severity of Adverse Events. An AE that met one or more of the following outcomes was classified as serious: * Fatal * Life-threatening * Disabling/incapacitating * Results in hospitalization or prolongs a hospital stay * A congenital abnormality * Other important medical events may also be considered serious AEs if they may require medical or surgical intervention to prevent one of the outcomes listed above.

    Time frame: From first dose date up to Week 24

Secondary outcomes

  1. PK Parameter: Ctau of EVG, Emtricitabine (FTC), Tenofovir (TFV), and Cobicistat (COBI) (Cohort 1)

    Ctau is defined as the observed drug concentration at the end of the dosing interval.

    Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 5 minutes, 0.25, 0.5, 1, 1.5, 2, 4, 5, 8 and 24 hours post-dose at Week 4

  2. PK Parameter: Ctau of EVG, FTC, TFV and COBI (Cohort 2)

    Ctau is defined as the observed drug concentration at the end of the dosing interval.

    Time frame: (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose at Week 4

  3. PK Parameter: Ctau of EVG, FTC, TFV, and COBI (Cohort 3)

    Ctau is defined as the observed drug concentration at the end of the dosing interval.

    Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 8 hours post-dose at Week 2

  4. PK Parameter: Cmax of EVG, TAF, FTC, TFV, and COBI (Cohort 1)

    Cmax is defined as the maximum concentration of drug.

    Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 5 minutes, 0.25, 0.5, 1, 1.5, 2, 4, 5, 8 and 24 hours post-dose at Week 4

  5. PK Parameter: Cmax of EVG, TAF, FTC, TFV, and COBI (Cohort 2)

    Cmax is defined as the maximum concentration of drug.

    Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose at Week 4

  6. PK Parameter: Cmax of EVG, TAF, FTC, TFV, and COBI (Cohort 3)

    Cmax is defined as the maximum concentration of drug.

    Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 8 hours post-dose at Week 2

  7. PK Parameter: CL/F of EVG and TAF (Cohort 1)

    Apparent oral clearance (CL/F) is defined as the apparent clearance of the drug following oral administration.

    Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 5 minutes, 0.25, 0.5, 1, 1.5, 2, 4, 5, 8 and 24 hours post-dose at Week 4

  8. PK Parameter: CL/F of EVG and TAF (Cohort 2)

    CL/F is defined as the apparent clearance of the drug following oral administration.

    Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose at Week 4

  9. PK Parameter: CL/F of EVG and TAF (Cohort 3)

    CL/F is defined as the apparent clearance of the drug following oral administration.

    Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 8 hours post-dose at Week 2

  10. PK Parameter: Vz/F of EVG and TAF (Cohort 1)

    Vz/F is defined as the apparent volume of distribution of the drug after oral administration.

    Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 5 minutes, 0.25, 0.5, 1, 1.5, 2, 4, 5, 8 and 24 hours post-dose at Week 4

  11. PK Parameter: Vz/F of EVG and TAF (Cohort 2)

    Vz/F is defined as the apparent volume of distribution of the drug after oral administration.

    Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose at Week 4

  12. PK Parameter: Vz/F of EVG and TAF (Cohort 3)

    Vz/F is defined as the apparent volume of distribution of the drug after oral administration.

    Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 8 hours post-dose at Week 2

  13. PK Parameter: AUCtau of FTC, TFV, and COBI (Cohort 1)

    AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval).

    Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 5 minutes, 0.25, 0.5, 1, 1.5, 2, 4, 5, 8 and 24 hours post-dose at Week 4

  14. PK Parameter: AUCtau of FTC, TFV, and COBI (Cohort 2)

    AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval).

    Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose at Week 4

  15. PK Parameter: AUCtau of FTC, TFV, and COBI (Cohort 3)

    AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval).

    Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 8 hours post-dose at Week 2

  16. Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, as Defined by the FDA Snapshot Analysis

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 24

  17. Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, as Defined by the FDA Snapshot Analysis

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 48

  18. Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, as Defined by the FDA Snapshot Analysis

    The percentage of participants with HIV-1 RNA \< 400 Copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 24

  19. Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, as Defined by the FDA Snapshot Analysis

    The percentage of participants with HIV-1 RNA \< 400 Copies/mL at Weeks 24 and 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 48

  20. Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, as Defined by the FDA Snapshot Analysis

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 24

  21. Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, as Defined by the FDA Snapshot Analysis

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 48

  22. Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, as Defined by the FDA Snapshot Analysis

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 24

  23. Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, as Defined by the FDA Snapshot Analysis

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 48

  24. Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Failure Analyses

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed based on missing = failure analyses.

    Time frame: Week 24

  25. Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Failure Analyses

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed based on missing = failure analyses.

    Time frame: Week 48

  26. Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, Based on Missing = Failure Analyses

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed based on missing = failure analyses.

    Time frame: Week 24

  27. Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, Based on Missing = Failure Analyses

    The percentage of participants with HIV-1 RNA \< 400 copies/mL at Week 48 was analyzed based on missing = failure analyses.

    Time frame: Week 48

  28. Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Failure Analyses

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed based on missing = failure analyses.

    Time frame: Week 24

  29. Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Failure Analyses

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed based on missing = failure analyses.

    Time frame: Week 48

  30. Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, Based on Missing = Failure Analyses

    The percentage of participants with HIV-1 RNA \< 400 copies/mL at Week 24 was analyzed based on missing = failure analyses.

    Time frame: Week 24

  31. Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, Based on Missing = Failure Analyses

    The percentage of participants with HIV-1 RNA \< 400 copies/mL at Week 48 was analyzed based on missing = failure analyses.

    Time frame: Week 48

  32. Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Failure Analyses

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed based on missing = failure analyses.

    Time frame: Week 24

  33. Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Failure Analyses

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed based on missing = failure analyses.

    Time frame: Week 48

  34. Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Excluded Analyses

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed based on missing = excluded analyses.

    Time frame: Week 24

  35. Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Excluded Analyses

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed based on missing = excluded analyses.

    Time frame: Week 48

  36. Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, Based on Missing = Excluded Analyses

    The percentage of participants with HIV-1 RNA \< 400 copies/mL at Week 24 was analyzed based on missing = excluded analyses.

    Time frame: Week 24

  37. Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, Based on Missing = Excluded Analyses

    The percentage of participants with HIV-1 RNA \< 400 copies/mL at Week 48 was analyzed based on missing = excluded analyses.

    Time frame: Week 48

  38. Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Excluded Analyses

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed based on missing = excluded analyses.

    Time frame: Week 24

  39. Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Excluded Analyses

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed based on missing = excluded analyses.

    Time frame: Week 48

  40. Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, Based on Missing = Excluded Analyses

    The percentage of participants with HIV-1 RNA \< 400 copies/mL at Week 24 was analyzed based on missing = excluded analyses.

    Time frame: Week 24

  41. Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, Based on Missing = Excluded Analyses

    The percentage of participants with HIV-1 RNA \< 400 copies/mL at Week 48 was analyzed based on missing = excluded analyses.

    Time frame: Week 48

  42. Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Excluded Analyses

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed based on missing = excluded analyses.

    Time frame: Week 24

  43. Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Excluded Analyses

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed based on missing = excluded analyses.

    Time frame: Week 48

  44. Cohort 1: Change From Baseline in Plasma log10 HIV-1 RNA at Week 24

    Time frame: Baseline, Week 24

  45. Cohort 1: Change From Baseline in Plasma log10 HIV-1 RNA at Week 48

    Time frame: Baseline, Week 48

  46. Cohort 1: Change From Baseline in Cluster of Differentiation (CD4+) Cell Count at Week 24

    Time frame: Baseline, Week 24

  47. Cohort 1: Change From Baseline in CD4+ Cell Count at Week 48

    Time frame: Baseline, Week 48

  48. Cohort 2: Change From Baseline in CD4+ Cell Count at Week 24

    Time frame: Baseline, Week 24

  49. Cohort 2: Change From Baseline in CD4+ Cell Count at Week 48

    Time frame: Baseline, Week 48

  50. Cohort 3: Change From Baseline in CD4+ Cell Count at Week 24

    Time frame: Baseline, Week 24

  51. Cohort 3: Change From Baseline in CD4+ Cell Count at Week 48

    Time frame: Baseline, Week 48

  52. Cohort 1: Change From Baseline in CD4+ Cell Percentage at Week 24

    Time frame: Baseline, Week 24

  53. Cohort 1: Change From Baseline in CD4+ Cell Percentage at Week 48

    Time frame: Baseline, Week 48

  54. Cohort 2: Change From Baseline in CD4+ Cell Percentage at Week 24

    Time frame: Baseline, Week 24

  55. Cohort 2: Change From Baseline in CD4+ Cell Percentage at Week 48

    Time frame: Baseline, Week 48

  56. Cohort 3: Change From Baseline in CD4+ Cell Percentage at Week 24

    Time frame: Baseline, Week 24

  57. Cohort 3: Change From Baseline in CD4+ Cell Percentage at Week 48

    Time frame: Baseline, Week 48

07

Results

Posted May 24, 2021

Participant flow

Participants were enrolled at study sites in South Africa, Thailand, Uganda, United States of America, and Zimbabwe.

Treatment Phase (48 Weeks)
Participant flow — Treatment Phase (48 Weeks)
MilestoneCohort 1: Age 12 to < 18 Years and Weight ≥ 35 kgCohort 2: Age 6 to < 12 Years and Weight ≥ 25 kgCohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg
Started505227
Completed485127
Not completed210
Withdrew: Withdrew consent110
Withdrew: Lost to follow-up100
Extension Phase
Participant flow — Extension Phase
MilestoneCohort 1: Age 12 to < 18 Years and Weight ≥ 35 kgCohort 2: Age 6 to < 12 Years and Weight ≥ 25 kgCohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg
Started485027
Completed444927
Not completed410
Withdrew: Pregnancy100
Withdrew: Investigator's discretion100
Withdrew: Non-compliance with study drug100
Withdrew: Lost to follow-up100
Withdrew: Withdrew consent010

Outcome measures

PrimaryPharmacokinetic (PK) Parameter: AUCtau of Elvitegravir (EVG) (Cohort 1)

AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval).

Time frame:
0 (pre-dose, ≤ 30 minutes prior to dosing), 5 minutes, 0.25, 0.5, 1, 1.5, 2, 4, 5, 8 and 24 hours post-dose at Week 4
Reported as:
Mean · hr*ng/mL
Pharmacokinetic (PK) Parameter: AUCtau of Elvitegravir (EVG) (Cohort 1)
hr*ng/mLCohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg
Pharmacokinetic (PK) Parameter: AUCtau of Elvitegravir (EVG) (Cohort 1)23840.1 ± 6076.15
PrimaryPK Parameter: AUCtau of EVG (Cohort 2)

AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval).

Time frame:
0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose at Week 4
Reported as:
Mean · hr*ng/mL
PK Parameter: AUCtau of EVG (Cohort 2)
hr*ng/mLCohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg
PK Parameter: AUCtau of EVG (Cohort 2)33813.9 ± 19536.30
PrimaryPK Parameter: AUCtau of EVG (Cohort 3)

AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval).

Time frame:
0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 8 hours post-dose at Week 2
Reported as:
Mean · hr*ng/mL
PK Parameter: AUCtau of EVG (Cohort 3)
hr*ng/mLCohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg
PK Parameter: AUCtau of EVG (Cohort 3)33245.6 ± 15499.22
PrimaryPK Parameter: AUClast of Tenofovir Alafenamide (TAF) (Cohort 1)

AUClast is defined as the concentration of drug from time zero to the last observable concentration, area under the concentration time curve to last observation (AUClast).

Time frame:
0 (pre-dose, ≤ 30 minutes prior to dosing), 5 minutes, 0.25, 0.5, 1, 1.5, 2, 4, 5, 8 and 24 hours post-dose at Week 4
Reported as:
Mean · hr*ng/mL
PK Parameter: AUClast of Tenofovir Alafenamide (TAF) (Cohort 1)
hr*ng/mLCohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg
PK Parameter: AUClast of Tenofovir Alafenamide (TAF) (Cohort 1)188.9 ± 105.45
PrimaryPK Parameter: AUClast of TAF (Cohort 2)

AUClast is defined as the concentration of drug from time zero to the last observable concentration.

Time frame:
0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose at Week 4
Reported as:
Mean · hr*ng/mL
PK Parameter: AUClast of TAF (Cohort 2)
hr*ng/mLCohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg
PK Parameter: AUClast of TAF (Cohort 2)332.9 ± 149.12
PrimaryPK Parameter: AUCtau of TAF (Cohort 3)

AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval).

Time frame:
0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 8 hours post-dose at Week 2
Reported as:
Mean · hr*ng/mL
PK Parameter: AUCtau of TAF (Cohort 3)
hr*ng/mLCohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg
PK Parameter: AUCtau of TAF (Cohort 3)366.4 ± 144.91
PrimaryCohort 1: Percentage of Participants With All Treatment-Emergent Adverse Events (AEs) and Treatment-Emergent Serious Adverse Events (SAEs)

Treatment-emergent adverse events (TEAEs) were defined as any AEs that begin or worsen on or after the start of study drug through 30 days after the last dose of study drug. The severity was graded based on the Gilead Sciences Grading Scale for Severity of Adverse Events. An AE that met one or more of the following outcomes was classified as serious: * Fatal * Life-threatening * Disabling/incapacitating * Results in hospitalization or prolongs a hospital stay * A congenital abnormality * Other important medical events may also be considered serious AEs if they may require medical or surgical intervention to prevent one of the outcomes listed above.

Time frame:
From first dose date up to Week 24
Reported as:
Number · percentage of participants
Cohort 1: Percentage of Participants With All Treatment-Emergent Adverse Events (AEs) and Treatment-Emergent Serious Adverse Events (SAEs)
percentage of participantsCohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg
Any TEAEs81.3
SAEs8.3
PrimaryCohort 2: Percentage of Participants With All Treatment-Emergent AEs and Treatment-Emergent SAEs

TEAEs were defined as any AEs that begin or worsen on or after the start of study drug through 30 days after the last dose of study drug. The severity was graded based on the Gilead Sciences Grading Scale for Severity of Adverse Events. An AE that met one or more of the following outcomes was classified as serious: * Fatal * Life-threatening * Disabling/incapacitating * Results in hospitalization or prolongs a hospital stay * A congenital abnormality * Other important medical events may also be considered serious AEs if they may require medical or surgical intervention to prevent one of the outcomes listed above.

Time frame:
From first dose date up to Week 24
Reported as:
Number · percentage of participants
Cohort 2: Percentage of Participants With All Treatment-Emergent AEs and Treatment-Emergent SAEs
percentage of participantsCohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg
Any TEAEs73.9
SAEs0
PrimaryCohort 3: Percentage of Participants With All Treatment-Emergent AEs and Treatment-Emergent SAEs

TEAEs were defined as any AEs that begin or worsen on or after the start of study drug through 30 days after the last dose of study drug. The severity was graded based on the Gilead Sciences Grading Scale for Severity of Adverse Events. An AE that met one or more of the following outcomes was classified as serious: * Fatal * Life-threatening * Disabling/incapacitating * Results in hospitalization or prolongs a hospital stay * A congenital abnormality * Other important medical events may also be considered serious AEs if they may require medical or surgical intervention to prevent one of the outcomes listed above.

Time frame:
From first dose date up to Week 24
Reported as:
Number · percentage of participants
Cohort 3: Percentage of Participants With All Treatment-Emergent AEs and Treatment-Emergent SAEs
percentage of participantsCohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg
Any TEAEs70.4
SAEs3.7
SecondaryPK Parameter: Ctau of EVG, Emtricitabine (FTC), Tenofovir (TFV), and Cobicistat (COBI) (Cohort 1)

Ctau is defined as the observed drug concentration at the end of the dosing interval.

Time frame:
0 (pre-dose, ≤ 30 minutes prior to dosing), 5 minutes, 0.25, 0.5, 1, 1.5, 2, 4, 5, 8 and 24 hours post-dose at Week 4
Reported as:
Mean · ng/mL
PK Parameter: Ctau of EVG, Emtricitabine (FTC), Tenofovir (TFV), and Cobicistat (COBI) (Cohort 1)
ng/mLCohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg
EVG300.8 ± 243.69
FTC102.4 ± 39.85
TFV10.0 ± 2.13
COBI25.0 ± 44.97
SecondaryPK Parameter: Ctau of EVG, FTC, TFV and COBI (Cohort 2)

Ctau is defined as the observed drug concentration at the end of the dosing interval.

Time frame:
(pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose at Week 4
Reported as:
Mean · ng/mL
PK Parameter: Ctau of EVG, FTC, TFV and COBI (Cohort 2)
ng/mLCohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg
EVG370.0 ± 438.52
FTC114.9 ± 27.70
TFV15.1 ± 3.77
COBI96.0 ± 162.01
SecondaryPK Parameter: Ctau of EVG, FTC, TFV, and COBI (Cohort 3)

Ctau is defined as the observed drug concentration at the end of the dosing interval.

Time frame:
0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 8 hours post-dose at Week 2
Reported as:
Mean · ng/mL
PK Parameter: Ctau of EVG, FTC, TFV, and COBI (Cohort 3)
ng/mLCohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg
EVG277.5 ± 223.43
FTC82.5 ± 26.47
TFV11.4 ± 2.65
COBI23.0 ± 23.02
SecondaryPK Parameter: Cmax of EVG, TAF, FTC, TFV, and COBI (Cohort 1)

Cmax is defined as the maximum concentration of drug.

Time frame:
0 (pre-dose, ≤ 30 minutes prior to dosing), 5 minutes, 0.25, 0.5, 1, 1.5, 2, 4, 5, 8 and 24 hours post-dose at Week 4
Reported as:
Mean · ng/mL
PK Parameter: Cmax of EVG, TAF, FTC, TFV, and COBI (Cohort 1)
ng/mLCohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg
EVG2229.6 ± 427.93
TAF166.8 ± 107.44
FTC2265.0 ± 510.55
TFV17.6 ± 4.18
COBI1202.4 ± 421.21
SecondaryPK Parameter: Cmax of EVG, TAF, FTC, TFV, and COBI (Cohort 2)

Cmax is defined as the maximum concentration of drug.

Time frame:
0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose at Week 4
Reported as:
Mean · ng/mL
PK Parameter: Cmax of EVG, TAF, FTC, TFV, and COBI (Cohort 2)
ng/mLCohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg
EVG3055.2 ± 1180.90
TAF313.3 ± 191.68
FTC3397.4 ± 916.06
TFV26.1 ± 5.43
COBI2079.4 ± 970.81
SecondaryPK Parameter: Cmax of EVG, TAF, FTC, TFV, and COBI (Cohort 3)

Cmax is defined as the maximum concentration of drug.

Time frame:
0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 8 hours post-dose at Week 2
Reported as:
Mean · ng/mL
PK Parameter: Cmax of EVG, TAF, FTC, TFV, and COBI (Cohort 3)
ng/mLCohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg
EVG3297.2 ± 1720.38
TAF286.6 ± 206.97
FTC3007.4 ± 1138.10
TFV19.6 ± 4.72
COBI1525.5 ± 788.12
SecondaryPK Parameter: CL/F of EVG and TAF (Cohort 1)

Apparent oral clearance (CL/F) is defined as the apparent clearance of the drug following oral administration.

Time frame:
0 (pre-dose, ≤ 30 minutes prior to dosing), 5 minutes, 0.25, 0.5, 1, 1.5, 2, 4, 5, 8 and 24 hours post-dose at Week 4
Reported as:
Mean · L/hr
PK Parameter: CL/F of EVG and TAF (Cohort 1)
L/hrCohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg
EVG6.7 ± 1.74
TAF68.6 ± 52.64
SecondaryPK Parameter: CL/F of EVG and TAF (Cohort 2)

CL/F is defined as the apparent clearance of the drug following oral administration.

Time frame:
0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose at Week 4
Reported as:
Mean · L/hr
PK Parameter: CL/F of EVG and TAF (Cohort 2)
L/hrCohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg
EVG6.3 ± 5.11
TAF31.9 ± 11.21
SecondaryPK Parameter: CL/F of EVG and TAF (Cohort 3)

CL/F is defined as the apparent clearance of the drug following oral administration.

Time frame:
0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 8 hours post-dose at Week 2
Reported as:
Mean · L/hr
PK Parameter: CL/F of EVG and TAF (Cohort 3)
L/hrCohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg
EVG3.4 ± 1.79
TAF18.5 ± 6.27
SecondaryPK Parameter: Vz/F of EVG and TAF (Cohort 1)

Vz/F is defined as the apparent volume of distribution of the drug after oral administration.

Time frame:
0 (pre-dose, ≤ 30 minutes prior to dosing), 5 minutes, 0.25, 0.5, 1, 1.5, 2, 4, 5, 8 and 24 hours post-dose at Week 4
Reported as:
Mean · liters
PK Parameter: Vz/F of EVG and TAF (Cohort 1)
litersCohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg
EVG60.5 ± 18.77
TAF49.7 ± 32.54
SecondaryPK Parameter: Vz/F of EVG and TAF (Cohort 2)

Vz/F is defined as the apparent volume of distribution of the drug after oral administration.

Time frame:
0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose at Week 4
Reported as:
Mean · liters
PK Parameter: Vz/F of EVG and TAF (Cohort 2)
litersCohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg
EVG46.8 ± 36.02
TAF28.6 ± 25.74
SecondaryPK Parameter: Vz/F of EVG and TAF (Cohort 3)

Vz/F is defined as the apparent volume of distribution of the drug after oral administration.

Time frame:
0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 8 hours post-dose at Week 2
Reported as:
Mean · liters
PK Parameter: Vz/F of EVG and TAF (Cohort 3)
litersCohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg
EVG28.5 ± 28.30
TAF16.3 ± 11.07
SecondaryPK Parameter: AUCtau of FTC, TFV, and COBI (Cohort 1)

AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval).

Time frame:
0 (pre-dose, ≤ 30 minutes prior to dosing), 5 minutes, 0.25, 0.5, 1, 1.5, 2, 4, 5, 8 and 24 hours post-dose at Week 4
Reported as:
Mean · hr*ng/mL
PK Parameter: AUCtau of FTC, TFV, and COBI (Cohort 1)
hr*ng/mLCohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg
FTC14424.4 ± 3452.88
TFV287.6 ± 54.09
COBI8240.8 ± 2972.94
SecondaryPK Parameter: AUCtau of FTC, TFV, and COBI (Cohort 2)

AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval).

Time frame:
0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose at Week 4
Reported as:
Mean · hr*ng/mL
PK Parameter: AUCtau of FTC, TFV, and COBI (Cohort 2)
hr*ng/mLCohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg
FTC20629.2 ± 3906.01
TFV440.2 ± 92.13
COBI15890.7 ± 8208.78
SecondaryPK Parameter: AUCtau of FTC, TFV, and COBI (Cohort 3)

AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval).

Time frame:
0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 8 hours post-dose at Week 2
Reported as:
Mean · hr*ng/mL
PK Parameter: AUCtau of FTC, TFV, and COBI (Cohort 3)
hr*ng/mLCohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg
FTC19468.1 ± 5635.74
TFV334.9 ± 76.77
COBI14485.2 ± 7166.10
SecondaryCohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, as Defined by the FDA Snapshot Analysis

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, as Defined by the FDA Snapshot Analysis
percentage of participantsCohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg
Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, as Defined by the FDA Snapshot Analysis90.0
SecondaryCohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, as Defined by the FDA Snapshot Analysis

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, as Defined by the FDA Snapshot Analysis
percentage of participantsCohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg
Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, as Defined by the FDA Snapshot Analysis92.0
SecondaryCohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, as Defined by the FDA Snapshot Analysis

The percentage of participants with HIV-1 RNA \< 400 Copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, as Defined by the FDA Snapshot Analysis
percentage of participantsCohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg
Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, as Defined by the FDA Snapshot Analysis94.0
SecondaryCohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, as Defined by the FDA Snapshot Analysis

The percentage of participants with HIV-1 RNA \< 400 Copies/mL at Weeks 24 and 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, as Defined by the FDA Snapshot Analysis
percentage of participantsCohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg
Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, as Defined by the FDA Snapshot Analysis94.0
SecondaryCohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, as Defined by the FDA Snapshot Analysis

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, as Defined by the FDA Snapshot Analysis
percentage of participantsCohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg
Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, as Defined by the FDA Snapshot Analysis100.0 (93.2 to 100.0)
SecondaryCohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, as Defined by the FDA Snapshot Analysis

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, as Defined by the FDA Snapshot Analysis
percentage of participantsCohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg
Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, as Defined by the FDA Snapshot Analysis98.1 (89.7 to 100.0)
SecondaryCohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, as Defined by the FDA Snapshot Analysis

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, as Defined by the FDA Snapshot Analysis
percentage of participantsCohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg
Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, as Defined by the FDA Snapshot Analysis96.3 (81.0 to 99.9)
SecondaryCohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, as Defined by the FDA Snapshot Analysis

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, as Defined by the FDA Snapshot Analysis
percentage of participantsCohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg
Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, as Defined by the FDA Snapshot Analysis96.3 (81.0 to 99.9)
SecondaryCohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Failure Analyses

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed based on missing = failure analyses.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Failure Analyses
percentage of participantsCohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg
Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Failure Analyses90.0 (78.2 to 96.7)
SecondaryCohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Failure Analyses

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed based on missing = failure analyses.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Failure Analyses
percentage of participantsCohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg
Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Failure Analyses92.0 (80.8 to 97.8)
SecondaryCohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, Based on Missing = Failure Analyses

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed based on missing = failure analyses.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, Based on Missing = Failure Analyses
percentage of participantsCohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg
Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, Based on Missing = Failure Analyses94.0
SecondaryCohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, Based on Missing = Failure Analyses

The percentage of participants with HIV-1 RNA \< 400 copies/mL at Week 48 was analyzed based on missing = failure analyses.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, Based on Missing = Failure Analyses
percentage of participantsCohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg
Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, Based on Missing = Failure Analyses94.0
SecondaryCohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Failure Analyses

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed based on missing = failure analyses.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Failure Analyses
percentage of participantsCohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg
Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Failure Analyses100.0 (93.2 to 100.0)
SecondaryCohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Failure Analyses

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed based on missing = failure analyses.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Failure Analyses
percentage of participantsCohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg
Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Failure Analyses100.0 (93.2 to 100.0)
SecondaryCohort 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, Based on Missing = Failure Analyses

The percentage of participants with HIV-1 RNA \< 400 copies/mL at Week 24 was analyzed based on missing = failure analyses.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, Based on Missing = Failure Analyses
percentage of participantsCohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg
Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, Based on Missing = Failure Analyses100.0
SecondaryCohort 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, Based on Missing = Failure Analyses

The percentage of participants with HIV-1 RNA \< 400 copies/mL at Week 48 was analyzed based on missing = failure analyses.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, Based on Missing = Failure Analyses
percentage of participantsCohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg
Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, Based on Missing = Failure Analyses100.0
SecondaryCohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Failure Analyses

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed based on missing = failure analyses.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Failure Analyses
percentage of participantsCohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg
Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Failure Analyses96.3 (81.0 to 99.9)
SecondaryCohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Failure Analyses

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed based on missing = failure analyses.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Failure Analyses
percentage of participantsCohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg
Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Failure Analyses96.3 (81.0 to 99.9)
SecondaryCohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Excluded Analyses

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed based on missing = excluded analyses.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Excluded Analyses
percentage of participantsCohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg
Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Excluded Analyses93.8 (82.8 to 98.7)
SecondaryCohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Excluded Analyses

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed based on missing = excluded analyses.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Excluded Analyses
percentage of participantsCohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg
Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Excluded Analyses95.8 (85.7 to 99.5)
SecondaryCohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, Based on Missing = Excluded Analyses

The percentage of participants with HIV-1 RNA \< 400 copies/mL at Week 24 was analyzed based on missing = excluded analyses.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, Based on Missing = Excluded Analyses
percentage of participantsCohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg
Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, Based on Missing = Excluded Analyses97.9
SecondaryCohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, Based on Missing = Excluded Analyses

The percentage of participants with HIV-1 RNA \< 400 copies/mL at Week 48 was analyzed based on missing = excluded analyses.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, Based on Missing = Excluded Analyses
percentage of participantsCohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg
Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, Based on Missing = Excluded Analyses97.9
SecondaryCohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Excluded Analyses

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed based on missing = excluded analyses.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Excluded Analyses
percentage of participantsCohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg
Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Excluded Analyses100.0 (93.2 to 100.0)
SecondaryCohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Excluded Analyses

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed based on missing = excluded analyses.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Excluded Analyses
percentage of participantsCohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg
Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Excluded Analyses100.0 (93.2 to 100.0)
SecondaryCohort 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, Based on Missing = Excluded Analyses

The percentage of participants with HIV-1 RNA \< 400 copies/mL at Week 24 was analyzed based on missing = excluded analyses.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, Based on Missing = Excluded Analyses
percentage of participantsCohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg
Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, Based on Missing = Excluded Analyses100.0
SecondaryCohort 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, Based on Missing = Excluded Analyses

The percentage of participants with HIV-1 RNA \< 400 copies/mL at Week 48 was analyzed based on missing = excluded analyses.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, Based on Missing = Excluded Analyses
percentage of participantsCohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg
Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, Based on Missing = Excluded Analyses100.0
SecondaryCohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Excluded Analyses

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed based on missing = excluded analyses.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Excluded Analyses
percentage of participantsCohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg
Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Excluded Analyses96.3 (81.0 to 99.9)
SecondaryCohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Excluded Analyses

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed based on missing = excluded analyses.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Excluded Analyses
percentage of participantsCohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg
Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Excluded Analyses96.3 (81.0 to 99.9)
SecondaryCohort 1: Change From Baseline in Plasma log10 HIV-1 RNA at Week 24
Time frame:
Baseline, Week 24
Reported as:
Mean · copies/mL
Cohort 1: Change From Baseline in Plasma log10 HIV-1 RNA at Week 24
copies/mLCohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg
Baseline4.62 ± 0.587
Change at Week 24-3.25 ± 0.645
SecondaryCohort 1: Change From Baseline in Plasma log10 HIV-1 RNA at Week 48
Time frame:
Baseline, Week 48
Reported as:
Mean · copies/mL
Cohort 1: Change From Baseline in Plasma log10 HIV-1 RNA at Week 48
copies/mLCohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg
Baseline4.62 ± 0.587
Change at Week 48-3.26 ± 0.712
SecondaryCohort 1: Change From Baseline in Cluster of Differentiation (CD4+) Cell Count at Week 24
Time frame:
Baseline, Week 24
Reported as:
Mean · cells/μL
Cohort 1: Change From Baseline in Cluster of Differentiation (CD4+) Cell Count at Week 24
cells/μLCohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg
Baseline471 ± 212.2
Change at Week 24191 ± 175.2
SecondaryCohort 1: Change From Baseline in CD4+ Cell Count at Week 48
Time frame:
Baseline, Week 48
Reported as:
Mean · cells/μL
Cohort 1: Change From Baseline in CD4+ Cell Count at Week 48
cells/μLCohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg
Baseline471 ± 212.2
Change at Week 48224 ± 170.3
SecondaryCohort 2: Change From Baseline in CD4+ Cell Count at Week 24
Time frame:
Baseline, Week 24
Reported as:
Mean · cells/μL
Cohort 2: Change From Baseline in CD4+ Cell Count at Week 24
cells/μLCohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg
Baseline961 ± 275.5
Change at Week 24-118 ± 194.1
SecondaryCohort 2: Change From Baseline in CD4+ Cell Count at Week 48
Time frame:
Baseline, Week 48
Reported as:
Mean · cells/µL
Cohort 2: Change From Baseline in CD4+ Cell Count at Week 48
cells/µLCohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg
Baseline961 ± 275.5
Change at Week 48-66 ± 203.6
SecondaryCohort 3: Change From Baseline in CD4+ Cell Count at Week 24
Time frame:
Baseline, Week 24
Reported as:
Mean · cells/μL
Cohort 3: Change From Baseline in CD4+ Cell Count at Week 24
cells/μLCohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg
Baseline1153 ± 459.9
Change at Week 24-137 ± 278.3
SecondaryCohort 3: Change From Baseline in CD4+ Cell Count at Week 48
Time frame:
Baseline, Week 48
Reported as:
Mean · cells/µL
Cohort 3: Change From Baseline in CD4+ Cell Count at Week 48
cells/µLCohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg
Baseline1153 ± 459.9
Change at Week 48-179 ± 319.2
SecondaryCohort 1: Change From Baseline in CD4+ Cell Percentage at Week 24
Time frame:
Baseline, Week 24
Reported as:
Mean · percentage of CD4+ cell
Cohort 1: Change From Baseline in CD4+ Cell Percentage at Week 24
percentage of CD4+ cellCohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg
Baseline23.6 ± 8.80
Change at Week 247.7 ± 4.77
SecondaryCohort 1: Change From Baseline in CD4+ Cell Percentage at Week 48
Time frame:
Baseline, Week 48
Reported as:
Mean · percentage of CD4+ cell
Cohort 1: Change From Baseline in CD4+ Cell Percentage at Week 48
percentage of CD4+ cellCohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg
Baseline23.6 ± 8.80
Change at Week 489.3 ± 5.19
SecondaryCohort 2: Change From Baseline in CD4+ Cell Percentage at Week 24
Time frame:
Baseline, Week 24
Reported as:
Mean · percentage of CD4+ cell
Cohort 2: Change From Baseline in CD4+ Cell Percentage at Week 24
percentage of CD4+ cellCohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg
Baseline38.2 ± 6.44
Change at Week 24-0.8 ± 3.97
SecondaryCohort 2: Change From Baseline in CD4+ Cell Percentage at Week 48
Time frame:
Baseline, Week 48
Reported as:
Mean · percentage of CD4+ cell
Cohort 2: Change From Baseline in CD4+ Cell Percentage at Week 48
percentage of CD4+ cellCohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg
Baseline38.2 ± 6.44
Change at Week 48-0.6 ± 4.37
SecondaryCohort 3: Change From Baseline in CD4+ Cell Percentage at Week 24
Time frame:
Baseline, Week 24
Reported as:
Mean · percentage of CD4+ cell
Cohort 3: Change From Baseline in CD4+ Cell Percentage at Week 24
percentage of CD4+ cellCohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg
Baseline35.9 ± 6.73
Change at Week 240.0 ± 4.40
SecondaryCohort 3: Change From Baseline in CD4+ Cell Percentage at Week 48
Time frame:
Baseline, Week 48
Reported as:
Mean · percentage of CD4+ cell
Cohort 3: Change From Baseline in CD4+ Cell Percentage at Week 48
percentage of CD4+ cellCohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg
Baseline35.9 ± 6.73
Change at Week 480.2 ± 3.78

Adverse events

Collected over Up to 583 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg1/50 (2%)10/50 (20%)47/50 (94%)
Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg0/52 (0%)7/52 (13.5%)45/52 (86.5%)
Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg0/27 (0%)1/27 (3.7%)25/27 (92.6%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventCohort 1: Age 12 to < 18 Years and Weight ≥ 35 kgCohort 2: Age 6 to < 12 Years and Weight ≥ 25 kgCohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg
Suicide attemptPsychiatric disorders2/500/520/27
PneumoniaInfections and infestations0/501/521/27
UveitisEye disorders1/500/520/27
Visual impairmentEye disorders1/500/520/27
ConstipationGastrointestinal disorders1/500/520/27
Abscess limbInfections and infestations1/500/520/27
GastroenteritisInfections and infestations1/500/520/27
Radius fractureInjury, poisoning and procedural complications1/500/520/27
Road traffic accidentInjury, poisoning and procedural complications1/500/520/27
Ulna fractureInjury, poisoning and procedural complications1/500/520/27
Most frequent other events
Showing 10 of 63
Most frequent other events
EventCohort 1: Age 12 to < 18 Years and Weight ≥ 35 kgCohort 2: Age 6 to < 12 Years and Weight ≥ 25 kgCohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg
Upper respiratory tract infectionInfections and infestations20/5014/5214/27
Respiratory tract infectionInfections and infestations19/5011/524/27
CoughRespiratory, thoracic and mediastinal disorders8/507/529/27
NauseaGastrointestinal disorders15/502/520/27
DiarrhoeaGastrointestinal disorders14/507/522/27
MalariaInfections and infestations14/504/520/27
HeadacheNervous system disorders14/508/521/27
VomitingGastrointestinal disorders12/5013/524/27
Abdominal painGastrointestinal disorders11/5010/520/27
NasopharyngitisInfections and infestations3/502/525/27

Baseline characteristics

The Safety Analysis Set included all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kgCohort 2: Age 6 to < 12 Years and Weight ≥ 25 kgCohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kgTotal
Mean15 ± 1.910 ± 1.26 ± 1.911 ± 3.7
Age, Customized
Age, Customized(Participants)Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kgCohort 2: Age 6 to < 12 Years and Weight ≥ 25 kgCohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kgTotal
2 to <6 Years001111
6 to <12 Years0521668
12 to <18 Years500050
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kgCohort 2: Age 6 to < 12 Years and Weight ≥ 25 kgCohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kgTotal
Female28301775
Male22221054
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kgCohort 2: Age 6 to < 12 Years and Weight ≥ 25 kgCohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kgTotal
Hispanic or Latino0000
Not Hispanic or Latino505227129
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kgCohort 2: Age 6 to < 12 Years and Weight ≥ 25 kgCohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kgTotal
American Indian or Alaska Native0000
Asian613322
Native Hawaiian or Other Pacific Islander0000
Black or African American443724105
White0202
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kgCohort 2: Age 6 to < 12 Years and Weight ≥ 25 kgCohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kgTotal
South Africa301316
Thailand613120
Uganda3027865
United States1112326
Zimbabwe0022
08

Study locations

16 sites
  • Miller's Children Hospital
    Long Beach, California 90806, United States
  • Children's Research Institute
    Washington D.C., District of Columbia 20010, United States
  • Emory University School of Medicine
    Atlanta, Georgia 30322, United States
  • St. Jude Children's Research Hospital
    Memphis, Tennessee 38105, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105-0371, United States
  • KIDCRU Ward J8
    Cape Town, 7505, South Africa
  • Be Part Yoluntu Centre
    Cape Town, 7646, South Africa
  • Desmond Tutu HIV Foundation
    Cape Town, 7705, South Africa
  • Perinatal HIV Research Unit Baragwanath Hospital
    Johannesburg, 1862, South Africa
  • Clinical HIV Research Unit
    Johannesburg, 2041, South Africa
  • Empilweni Services and Research Unit (ESRU)
    Johannesburg, 2092, South Africa
  • The HIV Netherlands Australia Thailand Research collaboration (HIV-NAT)
    Bangkok, 10330, Thailand
  • Queen Savang Vadhana Memorial Hospital
    Chon Buri, 20110, Thailand
  • Department of Pediatrics, Faculty of Medicine, Khon Kaen University
    Khon Kaen, 40002, Thailand
  • Joint Clinical Research Centre
    Kampala, PO Box 10005, Uganda
  • University of Zimbabwe - Clinical Research Centre
    Belgravia, 263, Zimbabwe
09

References and documents

Publications

  • Rakhmanina N, Gaur A, Natukunda E, Chokephaibulkit K, Liberty A, Kido A, et al. Acceptability and palatability of the single-tablet regimens of B/F/TAF and E/C/F/TAF in children (6-12 years) living with HIV infection [Abstract 33]. 10th International Workshop on HIV Pediatrics; 2018 July 21-22; Amsterdam, The Netherlands
  • Sharma S, Gupta S, Majeed S, Strehlau R, Hellstrom E, Liu Y, et al. Exposure-Safety of Tenofovir in Pediatric HIV-Infected Participants: Comparison of Tenofovir Alafenamide & Tenofovir Disoproxil Fumarate [Abstract 23]. 10th International Workshop on HIV Pediatrics; 2018 July 21-22; Amsterdam, The Netherlands.
  • Natukunda E, Gaur AH, Kosalaraksa P, Batra J, Rakhmanina N, Porter D, Shao Y, Zhang H, Pikora C, Rhee MS. Safety, efficacy, and pharmacokinetics of single-tablet elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed, HIV-infected children: a single-arm, open-label trial. Lancet Child Adolesc Health. 2017 Sep;1(1):27-34. doi: 10.1016/S2352-4642(17)30009-3. Epub 2017 Jun 29. PubMed 30169223 ↗
  • Rakhmanina N, Natukunda E, Kosalaraksa P, Batra J, Gaur A, Shao Y, et al. Safety and efficacy of E/C/F/TAF in virologically suppressed, HIV-infected children through 48 weeks [Abstract 32]. 9th International Workshop on HIV Pediatrics; 2017 July 21-22; Paris, France.
  • Gaur A, Natukunda E, Kosalarksa P, Batra J, Rakhmanina N, Coluci A, et al. Pharmacokinetics, Safety, and Efficacy of E/C/F/TAF in HIV-1-Infected Children (6 to <12 years) [Poster 424]. Conference on Retroviruses and Opportunistic Infections (CROI); 2017 February 13-16; Seattle Washington.
  • Gaur AH, Kizito H, Prasitsueubsai W, Rakhmanina N, Rassool M, Chakraborty R, Batra J, Kosalaraksa P, Luesomboon W, Porter D, Shao Y, Myers M, Ting L, SenGupta D, Quirk E, Rhee MS. Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial. Lancet HIV. 2016 Dec;3(12):e561-e568. doi: 10.1016/S2352-3018(16)30121-7. Epub 2016 Oct 17. PubMed 27765666 ↗
  • Gaur A, Kizito H, Chakraborty R, Batra J, Kosalaraksa P, Luesomboon W, et al. Safety and Efficacy of E/C/F/TAF in HIV-1 Infected Treatment-Naive Adolescents [Poster 817]. Conference on Retroviruses and Opportunistic Infections (CROI); 2016 February 22-25; Boston, Massachusetts.
  • Natukunda E, Liberty A, Strehlau R, Hellstrom E, Hakim JG, Kaur H, et al. Safety, pharmacokinetics and efficacy of low dose E/C/F/TAF in virologically suppressed children ≥ 2 years old living with HIV. (Abstract OABLB0101) 23rd International AIDS Conference; 06-10 July 2020 (Virtual).
  • Natukunda E, Liberty A, Strehlau R, Hellstrom E, Hakim J, Kaur H, et al. Safety, pharmacokinetics, and efficacy of low dose E/C/F/TAF in virologically suppressed children ≥ 2 years old living with HIV. (Abstract 3) International Workshop on HIV Pediatrics 2020; 16-17 November 2020 (Virtual).
  • Liberty A, Strehlau R, Rakhmanina N, Chokephaibulkit K, Koziara J, Kaur H, et al. Acceptability and palatability of low dose B/F/TAF and E/C/F/TAF in children (≥ 2y) with HIV. (Abstract 57) International Workshop on HIV Pediatrics 2020; 16-17 November 2020 (Virtual).
  • Kizito H, Gaur A, Prasitsuebsai W, Rakhmanina N, Lawson E, Shao Y, et al. Safety, Efficacy and Pharmacokinetics of the Integrase Inhibitor-Based E/C/F/TAF Single-Tablet Regimen in Treatment-Naïve HIV-Infected Adolescents Through 24 Weeks of Treatment [Poster 953]. Conference on Retroviruses and Opportunistic Infections; 2015 February 23-26; Seattle, WA.
  • Porter DP, Bennett SR, Quirk E, Miller MD, White KL. Lack of Emergent Resistance in HIV-1-Infected Adolescents on Elvitegravir-Based STRs [Poster 952]. Conference on Retroviruses and Opportunistic Infections (CROI); 2015 23-26 February; Seattle, WA.
  • Kizito H, Gaur A, Prasitsuebsai W, Rakhmanina N, Lawson E, Shao Y, et al. Safety, Efficacy and Pharmacokinetics of the Integrase Inhibitor-Based E/C/F/TAF Single-Tablet Regimen in Treatment-Naïve HIV-Infected Adolescents Through 24 Weeks of Treatment [Poster 36]. 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy; 2015 26-28 May; Washington, DC.
  • Kizito H, Gaur A, Prasitsuebsai W, Rakhmanina N, Chokephaibulkit K, Fourie J, et al. Changes in renal laboratory markers and bone mineral density in treatment-naïve HIV-1-infected adolescents initiating INSTI-based single-tablet regimens containing tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) [Presentation #MOAB0104]. International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention; 2015 19-22 July; Vancouver, Canada.
  • Natukunda E, Gaur AH, Kosalaraksa P, Hellstrom E, Strehlau R, Liberty A, Cox S, Leisegang R, Palaparthy R, Crowe S, Vieira V, Kersey K, Rakhmanina N. Pharmacokinetics, safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in children with HIV aged from 2 years and weighing at least 14 kg. J Int AIDS Soc. 2025 Feb;28(2):e26414. doi: 10.1002/jia2.26414. PubMed 39888251 ↗
  • Natukunda E, Gaur AH, Deville JG, Kosalaraksa P, Strehlau R, Castano E, Liberty A, Crowe S, Palaparthy R, Vieira VA, Kersey K, Rakhmanina N, Gordon CM. Longitudinal Evaluation of Bone Safety in Children and Adolescents With HIV-1 Starting Tenofovir Alafenamide-Containing Antiretroviral Therapy. J Pediatric Infect Dis Soc. 2025 Aug 7;14(7):piaf062. doi: 10.1093/jpids/piaf062. PubMed 40632108 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy#Commitment

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gileadclinicaltrials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2013 to primary completion in May 2020, 84 months.

Results were first posted in May 2021, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2013
First posted
May 16, 2013
StartActual
May 6, 2013
Primary completionActual
May 11, 2020
CompletionActual
Jun 18, 2025
Results first posted
May 24, 2021
Last update
Jan 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01854775
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
May 16, 2013
Start date
May 6, 2013
Primary completion
May 11, 2020
Completion
Jun 18, 2025
Results posted
May 24, 2021
Last update
Jan 9, 2026

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide

Start the discussion